Information on the target
The target company is a leading player in the veterinary drugs sector, specializing in the development and commercialization of innovative pharmaceutical solutions for both companion and farm animals. In the first half of 2026, the company reported a revenue of €768 million, reflecting a robust growth of 7.4% at constant exchange rates compared to the same period in 2025. This growth was driven by a balanced performance across its segments, with companion animal products growing by 10.0% and farm animal products by 6.7%. The company’s strategic focus on its Supercharge platforms has significantly contributed to this growth, particularly in key therapeutic areas such as endocrinology and nutrition.
Industry overview in the target’s specific country
The veterinary drugs industry in the target's country has been experiencing a notable transformation, characterized by increasing demand for advanced healthcare solutions for animals. This growth is primarily fueled by rising pet ownership rates and heightened awareness of animal health and welfare among consumers. The companion animal segment, in particular, has seen a surge in demand for specialized products, including those targeting chronic conditions and preventive care, which has become a focal point for many pharmaceutical companies.
In addition to the companion animal market, the farm animal segment is also witnessing significant growth, driven by the need for improved livestock health and productivity. The increasing global population and the corresponding demand for protein have led to a greater emphasis on animal health management, resulting in a higher adoption of veterinary pharmaceuticals. The integration of technology in veterinary practices, such as telemedicine and digital health solutions, is further enhancing the industry's landscape, providing veterinarians with innovative tools to improve animal care.
Regulatory frameworks in the country are evolving to support the growth of the veterinary drugs market, with a focus on ensuring the safety and efficacy of animal health products. This has led to increased investment in research and development, as companies strive to bring new and effective treatments to market. Furthermore, the ongoing trend towards sustainability and responsible use of antibiotics in livestock is shaping the development of new veterinary solutions, aligning with consumer expectations and regulatory requirements.
The rationale behind the deal
The rationale behind the acquisition of the target company lies in its strong market position and growth potential within the veterinary drugs sector. The deal is expected to enhance the investor's portfolio by leveraging the target's innovative product offerings and established distribution channels. The integration of the target's Supercharge platforms will provide synergies that can drive further growth and improve operational efficiencies. Additionally, the acquisition aligns with the investor's strategic focus on the healthcare sector, particularly in areas with high unmet needs.
Information about the investor The investor is a prominent private equity firm with a strong track record in the healthcare sector, specializing in identifying and nurturing high-potential companies. With a commitment to driving value creation through operational improvements and strategic growth init…